InsidersTradesSigma
Follow the 东宝生物 share price and the full management transaction log of the company, a publicly traded company based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 东宝生物 has published 1 reports. Market capitalisation: €2.8bn. The latest transaction was disclosed on 19 December 2022 (Sale). Among the most active insiders: 孟根达日. The full history is free.
1
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€317
1 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,012 of 29,063 companies
39.2
score / 100
Value37
Quality41
FCF yld1.0%
Earn yld2.0%
EV/EBITDA20.1x
ROE3.2%
Gross mgn23%
Net mgn7.3%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 December 2022
关于 东宝生物
东宝生物是一家专注于健康和制药领域的公司，致力于生物产品的开发和生产。该公司在XSHE市场上市。